<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01228435</url>
  </required_header>
  <id_info>
    <org_study_id>10-134</org_study_id>
    <nct_id>NCT01228435</nct_id>
    <nct_alias>NCT01119495</nct_alias>
  </id_info>
  <brief_title>IPI-504 in NSCLC Patients With ALK Translocations</brief_title>
  <official_title>A Phase II Study of IPI-204, A Novel Hsp90 Inhibitor in NSCLC Patients With ALK Translocations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dana-Farber Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Infinity Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      IPI-504 blocks a protein that is in cancer cells and is also in normal cells. This protein is&#xD;
      called Heat Shock Protein-90 (Hsp90). Hsp90 helps protect certain other proteins from being&#xD;
      destroyed by cells. These proteins can mutate to give off signals that allow cancer cells to&#xD;
      keep growing. By blocking the function of Hsp90, we hope that the cancer cell will block the&#xD;
      mutated protein and cause the cancer cells to die. This drug have been used in other research&#xD;
      studies and in the laboratory and information from those other research studies suggests that&#xD;
      thsi drug may help to treat lung cancer with ALK mutations. In this research study, we are&#xD;
      looking to see what effects IPI-504 has in patients with lung cancer who have an ALK&#xD;
      mutation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  Participants will receive the study drug (IPI-504) twice weekly for two weeks followed&#xD;
           by 10 days without study treatment. This 3-week period is called a cycle. Participants&#xD;
           will receive a total of 4 doses per cycle. On the days the participant receives study&#xD;
           drug, they will come to the clinic and be given the IPI-504 by being. Participants will&#xD;
           continue to receive study drug for additional cycles as long as they are benefiting from&#xD;
           it and do not experience any severe side effects.&#xD;
&#xD;
        -  Participants will have CT scans to assess the size and location of their tumor. They may&#xD;
           also have a PET scan or a combination of PET/CT scans. Imaging will be done at the&#xD;
           beginning of treatment and every five to six weeks while on study to assess how the&#xD;
           tumor is responding to IPI-504.&#xD;
&#xD;
        -  The following tests and procedures will be done on the prior to the first dose of&#xD;
           IPI-504: physical examination, vital signs, routine blood tests, EKGs, serum or urine&#xD;
           pregnancy test (for women of child-bearing potential).&#xD;
&#xD;
        -  After the first dose of IPI-504, the following tests and procedures will be done: EKGs,&#xD;
           vital signs (pulse only).&#xD;
&#xD;
        -  For all other visit days throughout the study, the following exams, tests and procedures&#xD;
           will be done: physical examination, vital signs, blood tests, tumor imaging assessments,&#xD;
           MRI of the brain (if applicable), review of medications and answer questions about any&#xD;
           side effects or changes in health.&#xD;
&#xD;
        -  After the final dose of study drug the following tests and procedures will be done&#xD;
           within 30 days: physical examination, ECOG Performance status, blood tests, review of&#xD;
           medications and answer questions about any side effects of changes in health.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    slow accrual&#xD;
  </why_stopped>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">February 2012</completion_date>
  <primary_completion_date type="Actual">February 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response Rate</measure>
    <time_frame>2 years</time_frame>
    <description>The response rate was defined as the number of patients achieving a RECIST 1.0 defined response divided by the number of patients treated and was to be calculated separately for each arm. A response by RECIST criteria means that the pre-defined target lesions (sum of the longest diameters) had to decrease by 30% or more and this response needed to be confirmed on a second scan at least 4 weeks later.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Treatment-Emergent Adverse Events</measure>
    <time_frame>2 years</time_frame>
    <description>Further document the safety of this regimen. Treatment-emergent adverse events will be summarized by MedDRA coding terms and separate tabulations will be produced for treatment-emergent adverse events, treatment-emergent serious adverse events, discontinuations due to adverse events, and treatment-emergent events of at least Grade 3 severity. A treatment-emergent adverse event is defined as an adverse event that was deemed to be related to the study intervention.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">3</enrollment>
  <condition>Lung Cancer</condition>
  <condition>Stage IIIb Lung Cancer</condition>
  <condition>Stage IV Lung Cancer</condition>
  <arm_group>
    <arm_group_label>ALK-inhibitor naive</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>No prior exposure to ALK-inhibitor</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ALK-inhibitor pre-treated</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Prior exposure to ALK inhibitor</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IPI-504</intervention_name>
    <description>Given intravenously twice weekly for 2 weeks followed by 10 day off treatment</description>
    <arm_group_label>ALK-inhibitor naive</arm_group_label>
    <arm_group_label>ALK-inhibitor pre-treated</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients must have pathologically confirmed diagnosis of Stage IIIb (with malignant&#xD;
             pleural or pericardial effusion), Stage IV, or recurrent NSCLC.&#xD;
&#xD;
          -  Patients must have demonstrated ALK mutation&#xD;
&#xD;
          -  There is no requirement for a minimum or maximum number of prior therapies, however,&#xD;
             patients must have refused, be intolerant to or already received at least on standard&#xD;
             systemic therapy for lung cancer&#xD;
&#xD;
          -  Measureable disease by RECIST criteria. If a patient has received radiation therapy&#xD;
             then measurable disease must be outside the radiation field.&#xD;
&#xD;
          -  18 years of age or older&#xD;
&#xD;
          -  Life expectancy of at least 3 months&#xD;
&#xD;
          -  ECOG performance status of 0-2&#xD;
&#xD;
          -  Baseline studies for determining eligibility, except for ALK mutation status, must be&#xD;
             completed within 30 days of first study dose.&#xD;
&#xD;
          -  CT scan must be completed within 28 days prior to first study dose&#xD;
&#xD;
          -  Women of child-bearing potential (WBCP) defined as a sexually mature woman who has not&#xD;
             undergone a hysterectomy or who has not been naturally post-menopausal for at least 24&#xD;
             consecutive months must have a negative serum or urine pregnancy test within 2 weeks&#xD;
             of first study dose&#xD;
&#xD;
          -  All WCBP and all sexually active male patients must agree to use adequate methods of&#xD;
             birth control throughout the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Treatment for NSCLC with any approved or investigational product within 2 weeks of&#xD;
             Cycle 1, Dose 1 for any small molecule therapy; within 4 weeks of Cycle 1, Dose 1 for&#xD;
             any biologic or any conventional chemotherapy.&#xD;
&#xD;
          -  Concurrent radiation therapy is not permitted&#xD;
&#xD;
          -  Use of a medication or food that is clinically relevant CYP3A inhibitor or inducer&#xD;
             within 2 weeks prior to Cycle 1, Dose 1&#xD;
&#xD;
          -  Laboratory values as outlined in the protocol&#xD;
&#xD;
          -  Baseline QT corrected using Fridericia's correction method (QTcf) &gt; 470ms. Patients&#xD;
             with left bundle branch block are eligible regardless of QTcf, as long as serum&#xD;
             troponin is normal or undetectable&#xD;
&#xD;
          -  Presence of active infection or systemic use of antibiotics within 72 hours of&#xD;
             treatment&#xD;
&#xD;
          -  Significant co-morbid condition or disease which in the judgment of the investigator&#xD;
             would place the patient at undue risk or interfere with the study&#xD;
&#xD;
          -  Women who are pregnant or lactating&#xD;
&#xD;
          -  Previous treatment with 17-AAG, DMAG, or other known Hsp90 inhibitor&#xD;
&#xD;
          -  Sinus bradycardia secondary to intrinsic conduction system disease. Patients with&#xD;
             sinus bradycardia secondary to pharmacologic treatment may enroll if withdrawal of the&#xD;
             treatment results in normalization of the resting heart rate to within normal limits&#xD;
&#xD;
          -  Active keratitis or keratoconjunctivitis&#xD;
&#xD;
          -  Alkaline phosphatase &gt; 1.5 x ULN. Patients with bone metastases and an alkaline&#xD;
             phosphatase level &gt; 1/5 x ULN and less than or equal to 3 x ULN are eligible if they&#xD;
             meet the criteria outlined in the protocol&#xD;
&#xD;
          -  Prothrombin time (PT) and partial thromboplastin time (PTT) &gt; 1.5 x ULN unless the&#xD;
             patient is receiving warfarin. If the patient is receiving warfarin, the international&#xD;
             normalized ratio must be within therapeutic range&#xD;
&#xD;
          -  Patients with clinically active brain metastasis or an uncontrolled seizure disorder,&#xD;
             ongoing spinal cord compression, or carcinomatous meningitis. Patients with clinically&#xD;
             stable brain metastasis are eligible.&#xD;
&#xD;
          -  Patients with prior hepatic resection or hepatic-directed therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lecia V. Sequist, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02214</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <study_first_submitted>October 25, 2010</study_first_submitted>
  <study_first_submitted_qc>October 25, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 26, 2010</study_first_posted>
  <results_first_submitted>May 28, 2013</results_first_submitted>
  <results_first_submitted_qc>August 18, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 23, 2013</results_first_posted>
  <last_update_submitted>October 28, 2017</last_update_submitted>
  <last_update_submitted_qc>October 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 4, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Lecia V. Sequist</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>NSCLC</keyword>
  <keyword>IPI-504</keyword>
  <keyword>ALK translocation</keyword>
  <keyword>Hsp90 inhibitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients were recruited from the oncology clinic at Mass General from 6/10/10 to 9/26/11.</recruitment_details>
      <pre_assignment_details>The study was closed to accrual after 3 patients were enrolled over a 1-year period. It was determined that there were too many competing protocols and completion of the study as designed was not feasible.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>ALK-inhibitor Naive</title>
          <description>Patients in this arm has no prior exposure to ALK-inhibitor and were treated with IPI-504 at 225 mg/m2 twice a week for 2 weeks followed by 10 days off therapy, cycles repeated every 21 days.</description>
        </group>
        <group group_id="P2">
          <title>ALK-inhibitor Pre-treated</title>
          <description>Patients in this arm had prior exposure to an ALK inhibitor and were treated with IPI-504 at 225 mg/m2 twice a week for 2 weeks followed by 10 days off therapy, cycles repeated every 21 days.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>ALK-inhibitor Naive</title>
          <description>No prior exposure to ALK-inhibitor</description>
        </group>
        <group group_id="B2">
          <title>ALK-inhibitor Pre-treated</title>
          <description>Prior exposure to ALK inhibitor</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1"/>
            <count group_id="B2" value="2"/>
            <count group_id="B3" value="3"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="79"/>
                    <measurement group_id="B2" value="67.5" spread="14.8"/>
                    <measurement group_id="B3" value="71.3" spread="12.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Response Rate</title>
        <description>The response rate was defined as the number of patients achieving a RECIST 1.0 defined response divided by the number of patients treated and was to be calculated separately for each arm. A response by RECIST criteria means that the pre-defined target lesions (sum of the longest diameters) had to decrease by 30% or more and this response needed to be confirmed on a second scan at least 4 weeks later.</description>
        <time_frame>2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ALK-inhibitor Naive</title>
            <description>Patients in this arm has no prior exposure to ALK-inhibitor and were treated with IPI-504 at 225mg/m2 twice a week for 2 weeks followed by 10 days off with cycles repeating every 21 days.</description>
          </group>
          <group group_id="O2">
            <title>ALK-inhibitor Pre-treated</title>
            <description>Patients in this arm had received prior exposure to ALK-inhibitor and were treated with IPI-504 at 225mg/m2 twice a week for 2 weeks followed by 10 days off with cycles repeating every 21 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Response Rate</title>
          <description>The response rate was defined as the number of patients achieving a RECIST 1.0 defined response divided by the number of patients treated and was to be calculated separately for each arm. A response by RECIST criteria means that the pre-defined target lesions (sum of the longest diameters) had to decrease by 30% or more and this response needed to be confirmed on a second scan at least 4 weeks later.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Treatment-Emergent Adverse Events</title>
        <description>Further document the safety of this regimen. Treatment-emergent adverse events will be summarized by MedDRA coding terms and separate tabulations will be produced for treatment-emergent adverse events, treatment-emergent serious adverse events, discontinuations due to adverse events, and treatment-emergent events of at least Grade 3 severity. A treatment-emergent adverse event is defined as an adverse event that was deemed to be related to the study intervention.</description>
        <time_frame>2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ALK-inhibitor Naive</title>
            <description>Patients in this arm has no prior exposure to ALK-inhibitor and were treated with IPI-504 at 225mg/m2 twice a week for 2 weeks followed by 10 days off with cycles repeating every 21 days.</description>
          </group>
          <group group_id="O2">
            <title>ALK-inhibitor Pre-treated</title>
            <description>Patients in this arm had received prior exposure to ALK-inhibitor and were treated with IPI-504 at 225mg/m2 twice a week for 2 weeks followed by 10 days off with cycles repeating every 21 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment-Emergent Adverse Events</title>
          <description>Further document the safety of this regimen. Treatment-emergent adverse events will be summarized by MedDRA coding terms and separate tabulations will be produced for treatment-emergent adverse events, treatment-emergent serious adverse events, discontinuations due to adverse events, and treatment-emergent events of at least Grade 3 severity. A treatment-emergent adverse event is defined as an adverse event that was deemed to be related to the study intervention.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Treatment-emergent adverse events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment-emergent serious adverse events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>discontinuations due to adverse events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>treatment-emergent events â‰¥ grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 Year</time_frame>
      <group_list>
        <group group_id="E1">
          <title>ALK-inhibitor Naive</title>
          <description>No prior exposure to ALK-inhibitor</description>
        </group>
        <group group_id="E2">
          <title>ALK-inhibitor Pre-treated</title>
          <description>Prior exposure to ALK inhibitor</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Elevated AST</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgias</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The study was unable to accrue sufficient participants due to competing studies. Therefore, the study results are not sufficiently powered to draw any conclusions.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Lecia Sequist</name_or_title>
      <organization>Massachusetts General Hospital</organization>
      <phone>617-726-7812</phone>
      <email>lvsequist@partners.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

